Sung H. Ferlay J. Siegel R.L. et al.

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA: A Cancer J Clinicians. 71: 209-249Then E.O. Lopez M. Saleem S. et al.

Esophageal cancer: an updated surveillance epidemiology and end results database analysis.

World J Oncol. 11: 55-64Napier K.J. Scheerer M. Misra S.

Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities.

World J Gastrointest Oncol. 6: 112-120Plum P.S. Hölscher A.H. Pacheco Godoy K. et al.

Prognosis of patients with superficial T1 esophageal cancer who underwent endoscopic resection before esophagectomy-A propensity score-matched comparison.

Surg Endosc. 32: 3972-3980Pennathur A. Farkas A. Krasinskas A.M. et al.

Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy.

Ann Thorac Surg. 87 (): 1048-1054Hulscher J.B. van Sandick J.W. de Boer A.G. et al.

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

N Engl J Med. 347: 1662-1669Omloo J.M. Lagarde S.M. Hulscher J.B. et al.

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.

Ann Surg. 246 (): 992-1000Oppedijk V. van der Gaast A. van Lanschot J.J. et al.

Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

J Clin Oncol. 32: 385-391Chen G. Wang Z. Liu X.Y. et al.

Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy.

World J Surg. 31: 1107-1114Shah M.A. Kennedy E.B. Catenacci D.V. et al.

Treatment of locally advanced esophageal carcinoma: ASCO guideline.

J Clin Oncol. 38: 2677-2694Cunningham D. Allum W.H. Stenning S.P. et al.

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

N Engl J Med. 355: 11-20Shapiro J. van Lanschot J.J.B. Hulshof M. et al.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Lancet Oncol. 16: 1090-1098Mei W. Xian-Zhi G. Weibo Y. et al.

Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients.

Int J Radiat Oncol Biol Phys. 16: 325-327Gignoux M. Roussel A. Paillot B. et al.

The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World.

J Surg. 11: 426-432Nygaard K. Hagen S. Hansen H.S. et al.

Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer.

World J Surg. 16 (): 1104-1109Kumar T. Pai E. Singh R. et al.

Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials.

World J Surg Oncol. 18: 59Kelsen D.P. Ginsberg R. Pajak T.F. et al.

Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.

N Engl J Med. 339: 1979-1984Kelsen D.P. Winter K.A. Gunderson L.L. et al.

Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

J Clin Oncol. 25: 3719-3725Ancona E. Ruol A. Santi S. et al.

Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.

Cancer. 91: 2165-2174

resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.

The Lancet. 359: 1727-1733Allum W.H. Stenning S.P. Bancewicz J. et al.

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.

J Clin Oncol. 27: 5062-5067Gebski V. Burmeister B. Smithers B.M. et al.

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Lancet Oncol. 8: 226-234Sjoquist K.M. Burmeister B.H. Smithers B.M. et al.

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Lancet Oncol. 12: 681-692Fan N. Wang Z. Zhou C. et al.

Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: a network meta-analysis.

eClinicalMedicine. 42: 101183Zhou H.Y. Zheng S.P. Li A.L. et al.

Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).

EClinicalMedicine. 24: 100422Yang H. Liu H. Chen Y. et al.

Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial.

J Clin Oncol. 36: 2796-2803Walsh T.N. Noonan N. Hollywood D. et al.

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

N Engl J Med. 335: 462-467Tepper J. Krasna M.J. Niedzwiecki D. et al.

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

J Clin Oncol. 26: 1086-1092Mariette C. Dahan L. Mornex F. et al.

Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

J Clin Oncol. 32: 2416-2422van Hagen P. Hulshof M.C.C.M. van Lanschot J.J.B. et al.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

N Engl J Med. 366: 2074-2084Eyck B.M. Lanschot JJBv Hulshof M.C.C.M. et al.

Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial.

J Clin Oncol. 39: 1995-2004Stahl M. Walz M.K. Riera-Knorrenschild J. et al.

Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.

Eur J Cancer. 81: 183-190Ajani J.A. Xiao L. Roth J.A. et al.

A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.

Ann Oncol. 24: 2844-2849Mukherjee S. Hurt C.N. Gwynne S. et al.

NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.

Eur J Cancer. 74: 38-46Goodman K.A. Ou F.S. Hall N.C. et al.

Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial.

J Clin Oncol. 39: 2803-2815Ychou M. Boige V. Pignon J.P. et al.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

J Clin Oncol. 29: 1715-1721Al-Batran S.E. Homann N. Pauligk C. et al.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Lancet. 393: 1948-1957Burmeister B.H. Thomas J.M. Burmeister E.A. et al.

Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.

Eur J Cancer. 47: 354-360Klevebro F. Alexandersson von Döbeln G. Wang N. et al.

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.

Ann Oncol. 27: 660-667von Döbeln G.A. Klevebro F. Jacobsen A.B. et al.

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.

Dis Esophagus. 32Keegan N. Keane F. Cuffe S. et al.

ICORG 10-14: Neo-AEGIS: A randomized clinical trial of neoadjuvant and adjuvant chemotherapy (modified MAGIC regimen) versus neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the esophagus and esophagogastric junction.

J Clin Oncol. 32 ()Reynolds J.V. Preston S.R. O'Neill B. et al.

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

J Clin Oncol. 39: 4004Leong T. Smithers B.M. Michael M. et al.

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).

BMC Cancer. 15: 532Leong T. Smithers B.M. Haustermans K. et al.

TOPGEAR: a randomized, phase III Trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG.

Ann Surg Oncol. 24: 2252-2258Hoeppner J. Lordick F. Brunner T. et al.

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

BMC Cancer. 16: 503Nakamura K. Kato K. Igaki H. et al.

Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).

Jpn J Clin Oncol. 43: 752-755Kato K. Ito Y. Daiko H. et al.

A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study.

J Clin Oncol. 40: 238Elliott D.A. Nabavizadeh N. Kusano A.S. et al.

Locally Advanced Esophageal Chemoradiation Therapy Practice Patterns: Results From a National Survey of ASTRO Members.

Int J Radiat Oncol Biol Phys. 93: S219Ising M.S. Marino K. Trivedi J.R. et al.

Influence of neoadjuvant radiation dose on patients undergoing esophagectomy and survival in locally advanced esophageal cancer.

J Gastrointest Surg. 23: 670-678Engel S. Awerbuch A. Kwon D. et al.

Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis.

J Gastrointest Oncol. 10: 391-399Li Y. Liu H. Sun C. et al.

Comparison of clinical efficacy of neoadjuvant chemoradiation therapy between lower and higher radiation doses for carcinoma of the esophagus and gastroesophageal junction: a systematic review.

Int J Radiat Oncol Biol Phys. 111: 405-416Markar S. Gronnier C. Duhamel A. et al.

Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?.

J Clin Oncol. 33: 3866-3873Jiang D.M. Sim H.W. Espin-Garcia O. et al.

Chemoradiotherapy using carboplatin plus paclitaxel versus cisplatin plus fluorouracil for esophageal or gastroesophageal junction cancer.

Oncology. 99: 49-56Lopez A. Harada K. Chen H.C. et al.

Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.

Medicine (Baltimore). 99: e19295Wang T. Yu J. Liu M. et al.

The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.

Drug Des Devel Ther. 13: 539-553Messager M. Mirabel X. Tresch E. et al.

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.

BMC Cancer. 16: 318

Positron emission tomography imaging for gastroesophageal junction tumors.

Semin Radiat Oncol. 23: 10-15Noordman B.J. Spaander M.C.W. Valkema R. et al.

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.

Lancet Oncol. 19: 965-974Eyck B.M. van der Wilk B.J. Noordman B.J. et al.

Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer.

Trials. 22: 345Lordick F. Ott K. Krause B.J. et al.

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Lancet Oncol. 8: 797-805Ott K. Weber W.A. Lordick F. et al.

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

J Clin Oncol. 24: 4692-4698van der Wilk B.J. Noordman B.J. Neijenhuis L.K.A. et al.

Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study.

Ann Surg. 274: 1009-1016Noordman B.J. Wijnhoven B.P.L. Lagarde S.M. et al.

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.

BMC Cancer. 18: 142Stahl M. Stuschke M. Lehmann N. et al.

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

J Clin Oncol. 23: 2310-2317Bedenne L. Michel P. Bouché O. et al.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

J Clin Oncol. 25: 1160-1168Park S.R. Yoon D.H. Kim J.H. et al.

A randomized phase III trial on the role of esophagectomy in complete responders to preoperative chemoradiotherapy for esophageal squamous cell carcinoma (ESOPRESSO).

Anticancer Res. 39: 5123-5133Vincent J. Mariette C. Pezet D. et al.

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: chemoradiation followed by surgery versus chemoradiation alone.

Eur J Cancer. 51: 1683-1693Chow R. Murdy K. Vaska M. et al.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis.

Radiother Oncol. 165: 37-43Vellayappan B.A. Soon Y.Y. Ku G.Y. et al.

Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.

Cochrane Database Syst Rev. 8: Cd010511Ruhstaller T. Thuss-Patience P. Hayoz S. et al.

Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).

Ann Oncol. 29: 1386-1393Cunningham D. Stenning S.P. Smyth E.C. et al.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial.

Lancet Oncol. 18: 357-370Kelly R.J. Ajani J.A. Kuzdzal J. et al.

Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

N Engl J Med. 384: 1191-1203